Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10753079 | 0.94 | SMN1; SMN2 (0.60) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL11751919 | 0.93 | SMN1; SMN2 (0.58) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL2186656 | 0.88 | POLB (0.63) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL11694927 | 0.88 | POLB (0.68) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL9787811 | 0.86 | POLB (0.65) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL11694716 | 0.86 | POLB (0.65) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL11677768 | 0.83 | POLB (0.74) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL5584328 | 0.82 | POLB (0.61) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL9563206 | 0.81 | POLB (0.59) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL16674708 | 0.81 | POLB (0.59) | POLBSMN1; SMN2MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059790-B2 | Compounds, polymers and coating formulations that comprise at least one N-halamine precursor, a cationic center and a coating incorporation group | UNIVERSITY OF MANITOBA (CA) | 2021-07-13 | — | — | US | disclosed |
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1534696-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004011448-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, LDLR | POLB 4142/4885SMN1; SMN2 4364/4885MAPK1 1286/4885 |
| US-11059790-B2 | Compounds, polymers and coating formulations that comprise at least one N-halamine precursor, a cationic center and a coating incorporation group | NACA, HNMT, C9 | POLB 2269/4885SMN1; SMN2 2500/4885MAPK1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.